Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
April 19 — Ongoing deficiencies in how federal laboratories handle hazardous biological agents require updated polices and better oversight across the government, according to an April 19 GAO report.
The Government Accountability Office report, Comprehensive and Up-to-Date Policies and Stronger Oversight Mechanisms Needed to Improve Safety (GAO-16-305), follows up on incidents in 2014 and 2015 that led to potential human exposure to vials containing anthrax and smallpox (9 LSLR 620, 5/29/15). After reviewing eight departments and 15 agencies, the GAO concluded most of them had policies that weren't comprehensive, and some departments and agencies had policies that weren't up to date.
“Given the threat that hazardous biological agents pose to public and animal health and the U.S. economy, federal departments and agencies need to strengthen oversight of their high-containment laboratories,” the GAO said in the report, while acknowledging that federal reviews have made recommendations intended to strengthen federal and national oversight. “Nonetheless, we continued to find certain deficiencies in departments’ and agencies’ internal controls for the management of their high containment laboratories, as well as opportunities for improvement.”
The House Energy and Commerce Committee released the report the day before its Oversight and Investigations Subcommittee was scheduled to hold a hearing on biosafety. Lawmakers on the oversight panel have held hearings on biosafety following the anthrax and smallpox incidents, expressing frustration at that time (8 LSLR 730, 7/25/14).
Rep. Tim Murphy (R-Pa.), chairman of the oversight subcommittee, said in an April 19 statement that labs working with hazardous materials should have adequate procedures in place to protect the public.
“Safety lapses at our bioresearch labs have been a concern for quite some time. While I’m encouraged to hear that some improvements have been made after these lapses, the fact of the matter is that far too many have happened,” Murphy said.
The GAO made nearly three dozen recommendations, calling on departments to “develop and update policies to include missing elements, ensure that oversight activity results are reported to senior officials, and develop plans with time frames for implementing safety recommendations.”
The Department of Health and Human Services along with the Department of Defense have made progress in implementing recommendations from laboratory safety reviews but haven't developed sufficient implementation plans, the GAO said. But the GAO didn't consider the HHS to have comprehensive policies.
“HHS did not have department-level policies, and two of its three component agencies did not have all six key elements in their agency-level policies. Specifically, [the Centers for Disease Control and Prevention's] policies contained three of the six key policy elements, but policies that contained the requirements for training and inspections applied only to the agency’s select agent-registered laboratories,” the report said. “We also found that CDC’s and [the Food and Drug Administration's] policies did not contain requirements for incident reporting to senior department officials. In contrast, we considered [The National Institutes of Health’s] policies for laboratory management to be comprehensive because the agency’s policies contained all six key elements, including reporting incidents to senior department officials.”
The recommendations addressed departments throughout the government, including the Agriculture, Interior, Energy, Homeland Security and Defense departments. For the HHS specifically, the report included recommendations to:
In July 2014, missteps at the CDC led to the unintentional exposure of more than 80 personnel to potentially viable anthrax and highly pathogenic H5N1 bird flu virus (8 LSLR 730, 7/25/14).
To contact the reporter on this story: Jeannie Baumann in Washington email@example.com
To contact the editor responsible for this story: Randy Kubetin at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)